Madeline Huber
About Madeline Huber
Madeline Huber is a Senior Associate at OrbiMed, where she has worked since 2024. She previously held various roles at OrbiMed and gained experience in the healthcare sector through internships at notable companies.
Current Role at OrbiMed Advisors
Madeline Huber serves as a Senior Associate at OrbiMed Advisors, a position she has held since 2024. In this role, she is involved in various aspects of investment analysis and strategic initiatives within the firm. Her experience at OrbiMed spans several years, having previously worked as an Analyst from 2020 to 2022 and as an Associate in Private Equity/Venture Capital from 2022 to 2024.
Experience at OrbiMed Advisors
Madeline Huber's tenure at OrbiMed Advisors began in 2018 when she joined as a Junior Analyst in Private Equity/Venture Capital. She worked in this capacity for two years before advancing to an Analyst role. Her career progression within the firm reflects her growing expertise in investment strategies and market analysis.
Educational Background
Madeline Huber earned her Bachelor of Arts (B.A.) in Molecular Biology from Princeton University, where she studied from 2014 to 2018. This academic background provided her with a strong foundation in scientific principles, which she applies in her work within the healthcare investment sector.
Internship Experience
Madeline Huber has completed several internships that contributed to her professional development. She interned at Bristol-Myers Squibb in 2016, focusing on Corporate Business Development within the Mergers and Acquisitions Team. Additionally, she gained experience at Regeneron Pharmaceuticals in 2017, where she participated in business development and strategic planning at the Regeneron Genetics Center. Her early exposure to venture capital came from her internship at 5AM Ventures in 2015.
High School Education
Madeline Huber completed her high school education at Menlo School, where she studied from 2010 to 2014. This foundational education set the stage for her future academic and professional pursuits in the field of molecular biology and finance.